Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse dose-optimization in children with ADHD
NCT00500071Phase 4Completed
- Sponsor
- Takeda
- Start
- Jun 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Jun 2007; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00500071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500071.